12 Best Stocks Under $25 To Invest In Right Now

Page 8 of 11

4. Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Average Upside Potential: 39.99%

Share Price: $16.43

Teva Pharmaceutical Industries Limited (NYSE:TEVA) enables access to quality medicines and treatment options. Products offered by the company range from generics, innovative and biosimilar medicines, to over-the-counter treatments. Teva was established in 1901 and has its global headquarters based in Israel.

Teva has the privilege of being the global leader in generic medicine with the world’s largest medicine cabinet. The firm’s high-quality medicines serve almost 200 million people across six continents every day. The company has a portfolio of over 3,600 medicines and produces nearly 76 billion tablets and capsules a year. Additionally, Teva has shown consistent quarterly revenue growth since Q1 2023.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) closed a strong third quarter. The company posted revenues of $4.3 billion, up 13% year-over-year. Its innovative portfolio and generics business drove the strong quarterly performance. Other updates included Teva’s biosimilar candidate to Prolia (denosumab) being accepted for review by the US FDA and the European Medicines Agency, the UZEDY launch gaining momentum, and AUSTEDO demonstrating continued growth. UZEDY was approved by the FDA on April 28, 2023, for the treatment of schizophrenia in adults. Meanwhile, AUSTEDO is targeted at tardive dyskinesia and chorea associated with Huntington’s disease.

In conclusion, Teva Pharmaceutical Industries Limited (NYSE:TEVA) is one of the leading pharmaceutical companies in the world with a global reach and scale as well as a fully integrated R&D function. The firm remains on track to deliver meaningful access to medicines as well as continued growth for its shareholders.

Page 8 of 11